Contrasting CRISPR Therapeutics (NASDAQ:CRSP) and Roivant Sciences (NASDAQ:ROIV)

CRISPR Therapeutics (NASDAQ:CRSP) and Roivant Sciences (NASDAQ:ROIV) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, dividends, profitability and risk.

Earnings and Valuation

This table compares CRISPR Therapeutics and Roivant Sciences”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51 million	1,567.98	-$581.60 million	($4.76)	-11.96
Roivant Sciences	$7.53 million	3,277.88	-$299.77 million	($0.53)	-64.49

Roivant Sciences has higher revenue and earnings than CRISPR Therapeutics. Roivant Sciences is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for CRISPR Therapeutics and Roivant Sciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1	6	10	1	2.61
Roivant Sciences	1	1	10	1	2.85

CRISPR Therapeutics presently has a consensus price target of $68.06, indicating a potential upside of 19.56%. Roivant Sciences has a consensus price target of $35.14, indicating a potential upside of 2.80%. Given CRISPR Therapeutics’ higher probable upside, equities analysts clearly believe CRISPR Therapeutics is more favorable than Roivant Sciences.

Risk & Volatility

CRISPR Therapeutics has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500.

Insider & Institutional Ownership

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 5.2% of CRISPR Therapeutics shares are held by company insiders. Comparatively, 8.8% of Roivant Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares CRISPR Therapeutics and Roivant Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%
Roivant Sciences	-3,534.96%	-22.94%	-21.53%

Summary

Roivant Sciences beats CRISPR Therapeutics on 7 of the 13 factors compared between the two stocks.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.